Observational studyIndian journal of pharmacology2025
Effectiveness of disease-modifying agents in ameliorating multiple sclerosis - A cross-sectional observational study.
Observational study in Indian journal of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiple sclerosis (MS) - A chronic inflammatory demyelinating disorder of the central nervous system is notorious for causing progressive neurological deterioration. This affects the quality of life of these patients and their productivity. Various oral and injectable disease-modifying drugs (DMDs) are available for the treatment of MS. In spite of availability of many drugs, the quality of life of these patients continues to be perturbing. The present study was undertaken to assess the effectiveness of common therapy in MS.
methodsA single-center cross-sectional study was conducted from 2020 to 2021. Seventy-one MS patients on DMDs were recruited. Relevant clinical details were collected from the electronic medical records, and a quality-of-life questionnaire was administered telephonically. Assessment of drugs being prescribed, treatment effectiveness, and adverse drug reactions were calculated as frequency and percentage.
resultsFemale cases were 64.8%. 77.5% were relapsing-remitting type of MS. The initial presenting complaints varied from visual disturbances in 28.16%, paresthesia in 25.35%, and ataxia in 21.12%. No relapse episodes were reported in 21.12% of cases. 33.8% faced physical disabilities and 9.9% cognitive disabilities. 2.81% cases opined that their quality of life is good.
conclusionsDrug therapy is beneficial in providing remission and reducing relapse rates in MS. DMDs are effective in reducing the debilitating symptoms and preventing the progression of the disease, when begun immediately after the diagnosis is made.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.